Eledon Pharmaceuticals (ELDN) Invested Capital (2013 - 2026)

Eledon Pharmaceuticals has reported Invested Capital for 14 years, with the latest figure at $44.8 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 23.98% year-over-year to $44.8 million; the trailing twelve-month figure through Mar 2026 stood at $44.8 million (down 23.98% YoY), and the FY2025 full-year result was $81.1 million, up 29.85% from the prior year.
• Invested Capital for Q1 2026 stood at $44.8 million, down from $81.1 million in the prior quarter.
• The five-year high for Invested Capital was $156.3 million in Q1 2022, with the low at -$70.4 million in Q1 2024.
• Historically, Invested Capital has averaged $46.8 million across 5 years, with a median of $44.8 million in 2026.
• Annual changes were most pronounced in 2023 — Invested Capital sank 303.83% — and 2024, when it jumped 228.79%.
• Eledon Pharmaceuticals' Invested Capital stood at $23.8 million in 2022, then slumped by 303.83% to -$48.5 million in 2023, then jumped by 228.79% to $62.4 million in 2024, then increased by 29.85% to $81.1 million in 2025, then slumped by 44.79% to $44.8 million in 2026.
• The last three Invested Capital figures came in at $44.8 million (Q1 2026), $81.1 million (Q4 2025), and $35.4 million (Q3 2025), per Business Quant data.